You are here

Valneva

Valneva, Pfizer push back timeline for Lyme disease vaccine

Valneva, Pfizer push back timeline for Lyme disease vaccine

BioPharma Dive

Flag link:

Major readouts on the horizon for small developers

Major readouts on the horizon for small developers

EP Vantage

Aldeyra Therapeutics

Autolus Therapeutics

Bavarian Nordic

BioXcel Therapeutics

Editas Medicine

Mersana Therapeutics

NGM Biopharmaceuticals

Sutro BioPharma

Viking Therapeutics

Flag link:

Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025

Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025

Seeking Alpha

clinical trials

Flag link:

FDA accepts Valneva’s chikungunya vaccine BLA for priority review

FDA accepts Valneva’s chikungunya vaccine BLA for priority review

Pharmaceutical Business Review

chikungunya virus

Flag link:

Pfizer, Valneva remove half of participants from study of Lyme disease shot

Pfizer, Valneva remove half of participants from study of Lyme disease shot

BioPharma Dive

clinical trials

Flag link:

Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine

Weak data as booster for Comirnaty close off opportunity for Valneva's COVID-19 vaccine

Fierce Biotech

Flag link:

Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen

Pfizer-Valneva's Lyme vaccine triggers 6-month antibody response, validating phase 3 regimen

Fierce Biotech

clinical trials

Flag link:

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

PM Live

Flag link:

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

BioSpace

clinical trials

Flag link:

Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine

Pfizer Buys Stake in Valneva to Advance Lyme Disease Vaccine

BioSpace

Flag link:

Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

BioSpace

clinical trials

chikungunya virus

Flag link:

Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children

Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children

Biopharma Reporter

clinical trials

Flag link:

Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies

Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies

Fierce Biotech

clinical trials

Flag link:

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Small biotech says its Covid-19 vaccine spurs more antibodies than AstraZeneca’s. Will supply deals come now?

Endpoints

Flag link:

Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping

Valneva, hit by COVID contract chaos, sees Lyme disease vaccine drop-off in phase 2, but boosters helping

Fierce Biotech

clinical trials

Flag link:

Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial

Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial

Biopharma Reporter

chikungunya virus

clinical trials

Flag link:

Valneva's not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Valneva's not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Fierce Pharma

Flag link:

Valneva joins the phase 3 Covid-19 vaccine club

Valneva joins the phase 3 Covid-19 vaccine club

EP Vantage

clinical trials

Flag link:

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO

Fierce Biotech

Flag link:

Valneva takes COVID-19 vaccine candidate into Phase 3 trials

Valneva takes COVID-19 vaccine candidate into Phase 3 trials

Biopharma Reporter

clinical trials

Flag link:

Pages